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ABSTRACT
Objective: The objective of this research work was to develop mucoadhesive particulates gel of propranolol hydrochloride for intranasal delivery.
Method: Drug-loaded mucoadhesive particulates were prepared by spray drying technique using polymers such as HPMC K100 and Carbopol 934P. 
Batches were prepared according to 32 factorial designs.
Result: The mucoadhesive particulates prepared were evaluated for different parameters such as drug content, entrapment efficiency, mucoadhesive 
strength, and in vitro drug release. Infrared, X-ray powder diffraction, and differential scanning calorimetry study revealed that there was no 
interaction occurs between drug and excipients and confirming reduction in crystallinity. The swelling index and encapsulation efficiency were found 
to be (0.9266%), (97.44%), angle of repose, Carr’s compressibility index falls in acceptable limits. At the end of 10 hrs, optimized batch showed 
90.23% drug release and followed zero-order release kinetics.
Conclusion: Conclusion from the result of the studies such as increase in the concentration of polymers contributed in drug release retardation. 
Although the prepared formulation of nasal administration can be a value addition in treatment for heart diseases like angina pectoris, myocardial 
infraction.
Keywords: Mucoadhesive, Particulates, Propranolol hydrochloride, Intranasal.
INTRODUCTION
Among the non-invasive routes, the nasal administration offers 
promising potential as a viable alternative for the delivery of some 
drugs [1]. In the recent years, this route has received special attention 
as a convenient and reliable method for the systemic delivery of drugs, 
especially those that are ineffective by oral route [2]. Mucoadhesive 
drug delivery systems have been used to improve and enhance drug 
bioavailability because the systems can contact with the absorption 
surface and prolong residence time result in a better absorption. 
Furthermore, reduces the frequency of drug administration due to a 
reduction in mucociliary clearance [3].
Several polymers, particularly hydrophilic polymers containing 
numerous hydrogen bond (H- bond) forming groups (i.e., hydroxyl, 
carboxyl, amine, and amide groups) have been investigated for 
mucoadhesive properties. Microspheres can be described as small 
particles (in 1-1000 µm size range) for use as carriers of drugs and 
other therapeutic agents consisting of proteins or synthetic polymers 
which are biodegradable in nature. The term microsphere describes 
a monolithic spherical structure with the drug or therapeutic agent 
distributed throughout the matrix or encapsulated. Adhesion of drug 
delivery device to the mucosal membrane such as buccal, ocular, rectal, 
and nasal can be termed as bioadhesion [4].
Microspheric particles exhibit a prolonged residence time by intimate 
contact with the absorption site and produce better therapeutic action. 
In general, microspheric particles possess potential to be employed 
for targeted and controlled release of the drug, but incorporating 
mucoadhesive properties to particulates will furthermore improve 
absorption and bioavailability of the drugs. Mucoadhesive particulates 
used in nasal drug delivery absorb water into sphere matrix, resulting in 
swelling of sphere and formation of gel. The gel formation improves the 
nasal residential time and hence, improves consequent bioavailability. 
Another mechanism stated for improving nasal bioavailability is 
improving the nasal permeation by opening the tight junction of the 
nasal epithelium. Furthermore, particulates may also protect the drug 
from enzymatic metabolism and sustain drug release, prolonging its 
effect [5].
Propranolol hydrochloride, a beta-adrenoreceptor antagonist that 
can acutely lower the blood pressure in human by blocking receptors 
nonselectively, is typically prescribed to treat hypertension, myocardial 
infraction, and cardiac arrhythmias. It has a short biological half-life 
(3.9±0.4 h) and the problem with the oral delivery of propranolol is its 
low bioavailability (26%) due to presystemic metabolism. To overcome 
this problem, propranolol can be delivered via nasal route. In this work, 
an attempt was made to prepare gel based mucoadhesive particulates 
of propranolol hydrochloride to ensure satisfactory drug release in 
nasal cavity with the use of polymer and thereby to avoid first pass 
metabolism and prolong duration of action [6].
MATERIAL AND METHODS
Materials
Propranolol hydrochloride was a gift sample from IPCA Laboratories 
Ltd., Mumbai, India. Hydroxypropyl methylcellulose (K4M) was gifted 
from Colorcon Asia Pvt. Ltd, Goa. Carbopol 934P was received as gift 
sample from Snap Natural & Alginate Products Ltd., Tamil Nadu. 
Dichloromethane and methanol were procured from Loba Chemie Pvt. 
Ltd. Mumbai. All the reagents were used of analytical grade.
Preformulation study
Preformulation studies on the obtained sample of drug include physical 
tests such as physical state, odor, color, loss on drying, determination of 
λmax, and standard curve. For compatibility studies, infrared spectra 
of the physical mixture of the drug and the polymers and the individual 
drug were taken.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Preparation of mucoadhesive particulates
In this study, mucoadhesive particulates of propranolol hydrochloride 
(HCl) were prepared by spray drying technique. In this method weighed 
quantity of HPMC K100 and Carbopol 934P polymers was added in 
dichloromethane and methanol. Then, stirred this suspension and 
kept on the magnetic stirrer to make a homogeneous mixture. Weighed 
quantity of propranolol HCl was added to this homogeneous mixture 
and thoroughly mixed with a stirrer at 500 rpm. For the formation, the 
suspension was poured in a beaker and this was passed through the 
spray dryer. Three sets of particulates were prepared. In the first set, 
particulates of propranolol HCl were prepared using only hydroxypropyl 
methylcellulose K100 in different concentrations. In the second set, 
particulates of the drug were prepared using only Carbopol 934P 
in different concentrations. In the third set, particulates of the drug 
were prepared in a combination of polymers such as hydroxypropyl 
methylcellulose and Carbopol 934P [7]. The batches were prepared by 
32 factorial designs as per Table 1.
Evaluation of mucoadhesive particulates of propranolol HCl
Drug content
Drug content was performed to check dose uniformity in the 
formulation. About 50 mg particulates were weighed and powdered. 
The stock solution was prepared by dissolving drug powder equivalent 
to 10 mg in 10 ml phosphate buffer (pH 6.8). Stock solution was 
shaken for 20 minutes on a sonicator. This resulting solution is further 
diluted with phosphate buffer (pH 6.8) to achieve concentration 
up to 10 μg/ml and the absorbance measured at the 290 nm by 
ultraviolet (UV) spectrophotometer [8].
Drug entrapment efficiency
Particulates (50 mg) were crushed in a glass mortar, and pestle and 
the powdered particulates were suspended in 10 ml phosphate 
buffer (pH 6.8). After 24 hrs the solution was filtered, and the filtrate 
was analyzed for the drug content by UV spectrophotometer at 
290 nm [9,10].
Mucoadhesion testing by in vitro wash–off test
100 mg of particulates sample was placed over a nasal mucosal segment 
mounted on a tilted side at an angle of 45°. The effluent was run over 
the segment. The effluent was collected on a Whatman filter paper, and 
weight of detached particles was determined [9].
In vitro release study
The release rate of propranolol HCL from mucoadhesive particulates 
was determined using Franz diffusion test apparatus. The diffusion test 
was performed using 100 ml of phosphate buffer (pH 6.8) at 37±0.5°C 
and 100 rpm. 5 ml sample of diffusion medium was withdrawn from the 
diffusion apparatus at specific time intervals, and the withdrawn sample 
was replaced with fresh diffusion medium. The sample was filtered 
through a 0.45 membrane filter and diluted to a suitable concentration 
with respective diffusion medium. Absorbance of these solutions was 
measured at 290 nm wavelength using ultraviolet spectrophotometer 
(JascoV-630). Cumulative percentage drug release was calculated using 
an equation obtained from a standard curve. The drug release analyzed 
data were obtained using “PCP Disso V-3” software, India. To know the 
release mechanism of the drug from the device, the diffusion data were 
substituted in different kinetic equations [11,12].
Fourier transform infrared spectroscopy (FTIR)
FTIR studies were conducted to determine any possible interaction 
among drug and excipients used. IR absorption spectrum of propranolol 
HCl was determined by FTIR (Jasco V-530 model) using KBr dispersion 
method. Briefly, about 2 mg of sample of was ground thoroughly with 
previously dried KBr at 120°C for 30 minutes; uniformly mixed with 
drug sample and kept in the sample holder, spectra were recorded over 
the wave number 400-4000 cm−1. Infrared spectrums of pure drug, a 
physical mixture of ingredients of the formulation, optimized batches 
were recorded. From the overlay spectrum analysis, the compatibility 
of ingredients in the formulations was found out. Pure, completely 
dried KBr was used as blank and before running the sample [9].
Differential scanning calorimetry (DSC)
Thermograms of drug and optimized formulation were obtained using 
DSC (Pyris Diamond TG/DTA, Make-Perkin Elmer) equipped with an 
intarcooler. Platinum crucible used with alpha alumina powder as a 
reference to calibrate the DSC temperature and enthalpy scale. The 
powder samples of 2-10 mg were hermetically kept in the aluminum 
pan and heated at a constant rate 10°C per minute, over a temperature 
range of 35-250°C. Inert atmosphere was maintained by purging 
nitrogen at the flow rate of 150 ml/minutes [13].
Powder X-ray diffractometry (p-XRD)
Optimized batch of particulates was subjected to p-XRD study using 
X-ray diffractometer (Philips X-ray diffractometer, PW-3710). For 
this, the samples of pure drug and optimized batch of the same were 
irradiated with monochromatized CuKα radiation and analyzed 
between 10° to 70° (2θ) [14].
Scanning electron microscopy (SEM)
SEM JSM 6360 Japan has been used to determine particle size 
distribution, surface topography, texture and examine the morphology 
of fractured or sectioned surface. The same generally used for 
generating three-dimensional surface relief images derived from 
secondary electrons. The examination of polymeric drug delivery 
system can provide important information about the porosity and 
microstructure of the device [14].
Accelerated stability testing
Stability studies were conducted for a specific time period up to 15 and 
30 days for selected formulations, ambient temperature, and humidity 
50°C±2°C/75% RH±5% RH in stability chamber for 15 and 30 days. 
After 15 and 30 days’ sample were removed and characterized for % 
drug content and cumulative % release of optimized batch [15].
RESULT AND DISCUSSION
Preformulation study
The sample of propranolol hydrochloride was found to be white, 
odorless, and crystalline powder. The melting point of propranolol 
hydrochloride was found to be in the range of 161-164°C. The spectrum 
of pure propranolol HCl showed characteristic peaks at 1106 cm−1 
Table 1: Formulation design of mucoadhesive particulates
Batch No HPMC K100 (mg) Carbopol 934P (mg) Dichloromethane (ml) Methanol (ml) Drug (Propranolol HCL) in mg
F1 200 200 50 100 100
F2 200 300 60 120 100
F3 200 400 70 140 100
F4 300 200 60 120 100
F5 300 300 70 140 100
F6 300 400 80 160 100
F7 400 200 70 140 100
F8 400 300 80 160 100
F9 400 400 90 180 100
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(C-O stretching); 1452 cm−1 C=C (aromatic stretching); 1267 cm−1 (C-N 
stretching); 1158 cm−1 (C-O stretching); and 1399 cm−1 (CH3 bending). 
Loss on drying of the sample was not more than 0.5%. The λmax of 
propranolol HCl in water was found out to be 290 nm [10,16].
Evaluation of mucoadhesive system of propranolol HCl
Bulk density may influence flow property, porosity, dissolution, and 
other properties and depends on the particle size, shape and tendency 
of particles to adhere together. The bulk density of particulates was 
found between 0.441±0.011 and 0.660±0.025 g/cm3. This indicates 
good packing capacity of particulates. Carr’s index evaluated inter-
particulate cohesive properties with the angle of repose measurements, 
studied the effects of packing geometry of solids with bulk, and tapped 
density. Bulk density and tapped density measurements found that 
density of a powder depends on particle packing and that density 
changes as the powder consolidate. Carr’s index was found between 
4.79 and 14.28. Hausner’s ratio is a simple method to evaluate the 
stability of powder column and to estimate flow properties. Low range 
was observed for Hausner’s ratio that indicates good flowability. Many 
different types of angular properties have been employed to assess 
flowability. Angle of repose is suited for particles >150 m. Values of angle 
of repose ≤30° generally indicate the free-flowing material and angle of 
repose ≥40° suggest a poor flowing material. The angle of repose of all 
the formulations fell within the range of 23.86±0.20 - 31.1±0.2. The 
observed results suggest good flowability of the particulates. Drug 
content was in the range of 94.00±0.001 - 98.03±0.020 indicating 
good content uniformity in the prepared formulation [12-15]. Physical 
properties of propranolol HCl mucoadhesive particulates are shown in 
Table 2.
Percent moisture content
In the formulation of mucoadhesive particulates of propranolol HCl, 
polymers such as sodium alginate, HPMC K100, and Carbopol 934P 
are used. From swelling study, it is observed that particulates prepared 
with the highest HPMC K100 and Carbopol 934P concentration shows 
the highest swelling rate [15]. Increase in concentration of polymer 
in the formulation increases percent water absorption in the formulation. 
The moisture absorption ranges from 61.33±0.005 to 92.66±0.005 
shown in Table 3.
Drug entrapment efficiency
The drug entrapment efficiency of all the formulations was in the 
range between 92.00% and 99.06%. The results of drug entrapment 
efficiency are shown in Table 4. Drug entrapment efficiency of 
particulates increases with increase in the concentration of HPMC 
K100 and Carbopol 934P. From the results, HPMC K100 is having 
better entrapment efficiency than Carbopol 934P, so the formulation 
of particulates having HPMC K100 shows higher entrapment efficiency.
Mucoadhesion testing by in vitro wash–off test
Prepared mucoadhesive particulates were found good mucoadhesive 
strength. Particulates are evaluated for mucoadhesive strength in 
phosphate buffer (pH 6.8). The percent mucoadhesion of batch F9 was 
found to be good, maximum particulates adhere for a long time. As 
the concentration of mucoadhesive polymers increases adhesion time 
also increases. Mucoadhesive strength of all formulations in phosphate 
buffer (pH 6.8) is shown in Tables 5 and 6.
In vitro drug release studies
The drug release from different formulation was studied using a 
Franz diffusion cell, which has lesser liquid capacity mimicking nasal 
compartment. Accurately weighed propranolol HCL loaded (100 mg) 
was placed on the cellophane membrane in the donor compartment 
containing phosphate buffer (pH 6.8) maintained at 37±1°C. The 
samples were withdrawn at predetermined intervals, and fresh 
phosphate buffer was replaced up to 10 hr. Further to determine 
the concentration of propranolol HCL, the samples were sent for UV 
spectrophotometer studies. Tables 7 and 8 show percent cumulative 
release of the drug.
Treatment of diffusion data with different kinetic equations
Diffusion study was conducted using Franz diffusion apparatus. 
The study was conducted in 900 ml phosphate buffer (pH 6.8) for 
first 10 h. The drug release data were fitted to models representing 
zero-order (cumulative amount of drug released vs. time), first-
order (log percentage of drug unreleased vs. time), Higuchi’s 
(cumulative percentage of drug released vs. square root of time), 
and Korsmeyer’s equation (log cumulative percentage of drug 
released vs. time) kinetics to know the release mechanisms. The 
three parameters n-release exponent, k-release rate constant, and 
r-correlation coefficient were used to study the release mechanism. 
Table 2: Physical properties of particulates
Batch no Bulk density* Tapped density* Hausner’s ratio* Carr’s index* Angle of repose* Drug content*
F1 0.725±0.005 0.818±0.020 1.12±0.005 11.36±0.020 32.53±0.005 96.34±0.010
F2 0.783±0.001 0.903±0.120 1.15±0.023 13.36±0.020 33.38±0.011 97.01±0.005
F3 0.728±0.150 0.843±0.010 1.15±0.150 13.64±0.005 34.56±0.210 97.53±0.013
F4 0.695±0.230 0.738±0.230 1.06±0.003 5.82±0.013 33.66±0.003 95.17±0.020
F5 0.774±0.421 0.813±0.150 1.05±0.310 4.79±0.001 32.52±0.120 96.30±0.005
F6 0.666±0.010 0.766±0.300 0.10±0.010 13.05±0.003 36.86±0.001 94.00±0.001
F7 0.702±0.520 0.742±0.010 1.06±0.005 14.28±0.120 38.30±0.005 95.71±0.004
F8 0.733±0.320 0.830±0.050 1.13±0.030 13.61±0.200 34.87±0.031 97.51±0.010
F9 0.810±0.125 0.940±0.240 1.16±0.120 12.34±0.130 33.66±0.004 98.03±0.020
*Indicates average±standard deviation (n=3)
Table 3: Percent moisture absorption










*Indicates average±standard deviation (n=3)
Table 4: Drug entrapment efficiency










*Indicates average±standard deviation (n=3)
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Observed values are given in Table 9. Regression coefficient (r2) 
values of each kinetic model were compared to find out the best fit 
model. By comparing the r2 values of different models, zero-order 
model was found to be best fit, which has higher values of correlation 
coefficient.
In vitro diffusion data gave us information about the effect of change 
in polymer concentration on drug release and swelling capability of 
formulation. Formulation batches F1-F9 prepared by combination 
of HPMC K100 and Carbopol 934P polymer. Dissolution data of these 
all batches revealed that drug release decreases as concentration of 
polymers increases. From the dissolution studies of the formulations, 
formulation F9 was showing better drug release than other 
formulations with good mucoadhesion property. Hence, formulation F9 
was considered as the best formulation.
FTIR
FTIR spectra confirmed that there were no any structural or chemical 
changes. Results in Fig. 1 showed that there exists no chemical interaction 
between propranolol HCl and excipients used in the formulation hence; 
these can be used in the formulation of mucoadhesive particulates of 
propranolol HCl.
DSC
DSC examination was conducted for the study of the physical state of 
drug in the formulation. The pure drug and formulation batch F9 were 
evaluated. In Fig. 2, sharp melting transition of propranolol HCl (pure) 
was observed at 164.34°C (A curve). Same transition of propranolol 
HCL was observed in formulation batch F9 (B curve). The thermogram 
of pure propranolol HCl showed sharp endothermic peak starting 
at 160°C with melting peak at 164°C and ending at 169°C. In the 
thermograms of optimized batch, endothermic peak was obtained at 
Table 5: Percent mucoadhesive strength in phosphate buffer (pH 6.8)
Time (hours) F1* F2* F3* F4* F5*
1 96.21±0.34 97.06±0.38 98.07±0.55 98.47±0.54 98.57±0.41
2 95.21±0.78 96.00±0.12 94.32±0.33 96.33±0.44 97.81±0.79
3 93.23±0.9 95.43±0.47 91.65±0.29 93.06±0.77 96.33±0.12
4 91.98±0.76 94.55±0.23 85.34±0.06 91.13±0.16 95.49±0.47
5 89.18±0.83 93.87±0.78 82.29±0.08 87.44±0.69 94.81±0.33
6 85.76±0.93 92.19±0.20 79.05±0.59 84.55±0.90 93.90±0.11
7 84.23±0.90 91.78±0.48 78.00±0.74 83.33±0.41 92.51±0.66
8 83.13±0.45 90.03±0.10 77.55±0.98 82.52±0.83 91.65±0.42
9 82.20±0.34 89.45±0.58 76.13±0.45 81.03±0.65 90.13±0.32
10 81.34±0.69 88.73±0.54 75.00±0.37 80.33±0.93 89.00±0.30
*Indicates average±standard deviation (n=3)
Table 6: Percent mucoadhesive strength in phosphate buffer (pH 6.8)
Time (hours) F6* F7* F8* F9*
1 99.45±0.04 99.60±0.45 100.1±0.37 98.04±0.73
2 97.06±0.58 97.31±0.66 99.03±0.21 98.39±0.03
3 95.02±0.29 96.78±0.17 98.12±0.74 95.11±0.86
4 93.47±0.66 95.34±0.40 96.28±0.85 91.22±0.59
5 93.55±0.06 94.99±0.82 94.29±0.87 89.57±0.07
6 89.33±0.06 93.77±0.30 90.48±0.68 85.66±0.97
7 85.06±0.79 91.20±0.38 88.04±0.87 84.98±0.94
8 83.56±0.48 90.57±0.65 85.07±0.97 82.45±0.59
9 82.65±0.54 89.45±0.58 84.23±0.77 81.00±0.34
10 81.42±0.76 88.31±0.23 82.65±0.40 80.65±0.87
*Indicates average±standard deviation (n=3)
Table 7: Percent cumulative release of F1 to F5 batches
Time in hrs F1* F2* F3* F4* F5*
1 15.33±0.03 22.82±0.02 28.25±0.05 22.81±0.01 22.81±0.01
2 35.13±0.05 30.31±0.01 33.06±0.02 30.31±0.02 24.04±0.02
3 30.71±0.01 37.63±0.03 38.78±0.01 37.63±0.02 37.61±0.05
4 48.64±0.05 43.41±0.01 43.44±0.04 43.41±0.01 45.13±0.01
5 48.64±0.01 48.66±0.02 47.61±0.01 48.67±0.02 48.63±0.02
6 58.21±0.05 49.96±0.01 56.47±0.05 49.94±0.02 49.93±0.01
7 65.81±0.01 60.72±0.01 60.69±0.02 60.72±0.05 60.73±0.02
8 68.26±0.05 74.72±0.02 73.44±0.05 74.72±0.01 73.34±0.01
9 87.41±0.02 85.75±0.01 87.25±0.01 85.75±0.01 88.74±1.07
10 95.62±0.01 94.55±0.05 94.23±0.02 93.11±0.01 93.07±0.01
*Indicates average±standard deviation (n=3)
Table 8: Percent cumulative release of F6 to F9 batches
Time in 
hour
F6* F7* F8* F9*
1 28.24±0.02 15.34±0.04 28.25±0.05 22.82±0.02
2 33.05±0.02 35.12±0.01 33.07±0.01 24.06±0.01
3 38.77±0.02 30.72±0.02 38.64±0.23 37.62±0.02
4 43.46±0.02 42.70±0.05 43.46±0.02 45.11±0.01
5 47.61±0.02 46.71±0.11 47.62±0.02 48.64±0.02
6 56.71±0.01 58.20±0.05 52.86±0.02 59.94±0.03
7 60.73±0.01 66.33±0.01 60.76±0.02 60.72±0.02
8 73.43±0.01 68.55±0.02 73.44±0.01 73.32±0.02
9 86.31±0.02 85.44±0.01 85.81±0.05 83.75±0.04
10 92.75±0.01 92.74±0.05 91.63±0.01 90.23±0.01
*Indicates average±standard deviation (n=3)
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164.34°C. Slight shifting of endothermic peaks with a decrease in its 
intensity indicates amorphism of drug.
p-XRD
Powder X-ray diffraction study reveals information about the 
crystallographic structure and composition of materials [10,17]. 
Intensity of the peaks for the pure drug was sharp, but when it was 
incorporated into the polymer matrix, the intensities of the peaks 
decreases due to decreased crystallinity of the propranolol HCl. p-XRD 
of propranolol HCl and formulation batch F9 shows relative intensity 
the peaks of propranolol HCl have not been changed in the formulation. 
In the case of batch F9, the total number of peaks has been reduced 
due to a reduction in crystallinity of propranolol HCl and may be due to 
dilution of drug and polymers during the process.
SEM
The photographs of formulations taken by SEM are shown in Fig. 3. 
Particulates of propranolol HCl were approximately spherical or oval, 
and their surface was smooth giving them a good appearance. From the 
photographic observations in Fig. 3, it can be stated that soft and gel like 
nature of formulation indicated to retard the release of propranolol HCl.
Accelerated stability studies
Stability study was conducted for the formulations at 40±1°C and 75% 
RH for a period of 30 days. The samples were analyzed for drug content 
at different time intervals, and it is evident that there were slight 
changes in the content of drug as shown in Table 10.
For stability study, formulation batch F9 was kept for 30 days in 
stability chamber, and samples were taken after 30 days and analyzed 
for swelling index, mucoadhesion, encapsulation efficiency, drug 
content and % drug release after 10 hrs, which showed slight changes. 
This indicates that the formulation batch F9 was stable for a period of 
30 days at 40±1°C and 75% RH.
CONCLUSION
In this study, a satisfactory attempt has been done to formulate 
mucoadhesive particulates of propranolol HCL. From the experimental 
study, spray drying technique was successfully developed for 
formulation of sustained release mucoadhesive particulates of 
propranolol hydrochloride. The particulates prepared using HPMC 
Fig. 1: Overlain spectrums of pure drug (propranolol HCl) and 
optimized batch F9
Table 9: Kinetic data of propranolol HCl mucoadhesive particulates
Batch no Zero-order (R) First-order (R) Matrix model (R) Peppas model (R)
F1 0.9770 0.8746 0.9518 0.9754
F2 0.9672 0.8861 0.9551 0.9707
F3 0.9504 0.8926 0.9608 0.9512
F4 0.9683 0.9073 0.9605 0.9757
F5 0.9723 0.9030 0.9536 0.9521
F6 0.9486 0.9104 0.9535 0.9533
F7 0.9761 0.9136 0.9560 0.9753
F8 0.9456 0.9158 0.9622 0.9497
F9 0.9704 0.9302 0.9595 0.9654
Fig. 2: Differential scanning calorimetry thermograms 
(a) propranolol HCl, (b) optimized batch (F9)
Table 10: Evaluation of optimized formulation F9 after stability 
period
Parameters Time period
Before* After 30 days*
Swelling index 0.9266±0.005 0.9166±0.003
Mucoadhesion 96.48±0.24 95.47±0.22
Encapsulation 97.44±0.01 97.44±0.01
% Drug release after 10 hrs 90.23±0.01 90.22±0.001
Drug content (%) 98.03±0.02 98.00±0.01
*Indicates average±standard deviation (n=3)
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K100 and Carbopol 934P showed good results in terms of drug release, 
mucoadhesion strength and entrapment efficiency. It is concluded that 
the prepared drug delivery system containing mucoadhesive polymers 
can be considered as one of the promising formulation technique 
for preparing sustained drug delivery systems and hence, in the 
management of hypertensions.
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